Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Progyn
- Development stage
- Unknown
- Lead developer
- Astel Medica
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Progyn is an oral probiotic dietary supplement developed by Astel Medica specifically for women's intimate health and wellbeing. It is formulated as a capsule containing three specific strains of lactobacilli: *Lactobacillus brevis* PHA-131 (80 mg), *Lactobacillus acidophilus* PHA-122 (80 mg), and *Lactobacillus rhamnosus* PHA-152 (40 mg), providing approximately 2.5 billion live bacteria per capsule at production. The formulation also includes 20 mg of FructoOligoSaccharide (FOS), which acts as a prebiotic to support the growth of beneficial bacteria. Progyn is designed to restore and maintain the natural vaginal flora, ensuring intimate balance. It is marketed as a well-tolerated product suitable for use during pregnancy and breastfeeding.
- Brand names
- Progyn
Beyond the preview
Go deeper on Progyn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Progyn.